81 related articles for article (PubMed ID: 26634925)
1. An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo.
Lohse S; Meyer S; Meulenbroek LA; Jansen JH; Nederend M; Kretschmer A; Klausz K; Möginger U; Derer S; Rösner T; Kellner C; Schewe D; Sondermann P; Tiwari S; Kolarich D; Peipp M; Leusen JH; Valerius T
Cancer Res; 2016 Jan; 76(2):403-17. PubMed ID: 26634925
[TBL] [Abstract][Full Text] [Related]
2. IgA EGFR antibodies mediate tumour killing in vivo.
Boross P; Lohse S; Nederend M; Jansen JH; van Tetering G; Dechant M; Peipp M; Royle L; Liew LP; Boon L; van Rooijen N; Bleeker WK; Parren PW; van de Winkel JG; Valerius T; Leusen JH
EMBO Mol Med; 2013 Aug; 5(8):1213-26. PubMed ID: 23918228
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.
Lohse S; Brunke C; Derer S; Peipp M; Boross P; Kellner C; Beyer T; Dechant M; van der Winkel JG; Leusen JH; Valerius T
J Biol Chem; 2012 Jul; 287(30):25139-50. PubMed ID: 22679018
[TBL] [Abstract][Full Text] [Related]
4. Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody.
Brunke C; Lohse S; Derer S; Peipp M; Boross P; Kellner C; Beyer T; Dechant M; Royle L; Liew LP; Leusen JH; Valerius T
MAbs; 2013; 5(6):936-45. PubMed ID: 24492345
[TBL] [Abstract][Full Text] [Related]
5. Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting.
Meyer S; Nederend M; Jansen JH; Reiding KR; Jacobino SR; Meeldijk J; Bovenschen N; Wuhrer M; Valerius T; Ubink R; Boross P; Rouwendal G; Leusen JH
MAbs; 2016; 8(1):87-98. PubMed ID: 26466856
[TBL] [Abstract][Full Text] [Related]
6. IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.
Stip MC; Evers M; Nederend M; Chan C; Reiding KR; Damen MJ; Heck AJR; Koustoulidou S; Ramakers R; Krijger GC; de Roos R; Souteyrand E; Cornel AM; Dierselhuis MP; Jansen M; de Boer M; Valerius T; van Tetering G; Leusen JHW; Meyer-Wentrup F
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37479484
[TBL] [Abstract][Full Text] [Related]
7. Monitoring kinetics reveals critical parameters of IgA-dependent granulocyte-mediated anti-tumor cell cytotoxicity.
Zwick A; Bernhard M; Knoerck A; Linxweiler M; Schick B; Heinzelmann J; Smola S; Lohse S
J Immunol Methods; 2019 Oct; 473():112644. PubMed ID: 31404549
[TBL] [Abstract][Full Text] [Related]
8. Engineering Dimeric EGFR-directed IgA Antibodies Reveals a Central Role of CD147 during Neutrophil-mediated Tumor Cell Killing of Head and Neck Squamous Cancer Cells.
Zwick A; Braun FL; Weber LJ; Linder M; Linxweiler M; Lohse S
J Immunol; 2024 May; ():. PubMed ID: 38787053
[TBL] [Abstract][Full Text] [Related]
9. Characterization of human Fc alpha receptor transgenic mice: comparison of CD89 expression and antibody-dependent tumor killing between mouse strains.
Stip MC; Jansen JHM; Nederend M; Tsioumpekou M; Evers M; Olofsen PA; Meyer-Wentrup F; Leusen JHW
Cancer Immunol Immunother; 2023 Sep; 72(9):3063-3077. PubMed ID: 37338671
[TBL] [Abstract][Full Text] [Related]
10. Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma.
Evers M; Stip M; Keller K; Willemen H; Nederend M; Jansen M; Chan C; Budding K; Nierkens S; Valerius T; Meyer-Wentrup F; Eijkelkamp N; Leusen J
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34716207
[TBL] [Abstract][Full Text] [Related]
11. Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells.
Ye S; Fox MI; Belmar NA; Sho M; Chao DT; Choi D; Fang Y; Zhao V; Keller SF; Starling GC; Culp PA
J Immunol Res; 2017; 2017():5737159. PubMed ID: 29075649
[TBL] [Abstract][Full Text] [Related]
12. Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents.
van Tetering G; Evers M; Chan C; Stip M; Leusen J
Antibodies (Basel); 2020 Dec; 9(4):. PubMed ID: 33333967
[TBL] [Abstract][Full Text] [Related]
13. Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy.
Hart F; Danielczyk A; Goletz S
Bioengineering (Basel); 2017 May; 4(2):. PubMed ID: 28952521
[TBL] [Abstract][Full Text] [Related]
14. Allosteric Effects between the Antibody Constant and Variable Regions: A Study of IgA Fc Mutations on Antigen Binding.
Su CT; Lua WH; Ling WL; Gan SK
Antibodies (Basel); 2018 Jun; 7(2):. PubMed ID: 31544872
[TBL] [Abstract][Full Text] [Related]
15. Engineered therapeutic antibodies with enhanced effector functions: Clinical application of the Potelligent® Technology.
Matsushita T
Korean J Hematol; 2011 Sep; 46(3):148-50. PubMed ID: 22065966
[No Abstract] [Full Text] [Related]
16. Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.
Lohse S; Loew S; Kretschmer A; Jansen JHM; Meyer S; Ten Broeke T; Rösner T; Dechant M; Derer S; Klausz K; Kellner C; Schwanbeck R; French RR; Tipton TRW; Cragg MS; Schewe DM; Peipp M; Leusen JHW; Valerius T
Br J Haematol; 2018 May; 181(3):413-417. PubMed ID: 28449349
[No Abstract] [Full Text] [Related]
17. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.
Rezvani K; Rouce RH
Front Immunol; 2015; 6():578. PubMed ID: 26635792
[TBL] [Abstract][Full Text] [Related]
18. IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding.
Ternant D; Arnoult C; Pugnière M; Dhommée C; Drocourt D; Perouzel E; Passot C; Baroukh N; Mulleman D; Tiraby G; Watier H; Paintaud G; Gouilleux-Gruart V
J Immunol; 2016 Jan; 196(2):607-13. PubMed ID: 26685205
[TBL] [Abstract][Full Text] [Related]
19. The Art of Destruction: Optimizing Collision Energies in Quadrupole-Time of Flight (Q-TOF) Instruments for Glycopeptide-Based Glycoproteomics.
Hinneburg H; Stavenhagen K; Schweiger-Hufnagel U; Pengelley S; Jabs W; Seeberger PH; Silva DV; Wuhrer M; Kolarich D
J Am Soc Mass Spectrom; 2016 Mar; 27(3):507-19. PubMed ID: 26729457
[TBL] [Abstract][Full Text] [Related]
20. Agonistic Human Antibodies Binding to Lecithin-Cholesterol Acyltransferase Modulate High Density Lipoprotein Metabolism.
Gunawardane RN; Fordstrom P; Piper DE; Masterman S; Siu S; Liu D; Brown M; Lu M; Tang J; Zhang R; Cheng J; Gates A; Meininger D; Chan J; Carlson T; Walker N; Schwarz M; Delaney J; Zhou M
J Biol Chem; 2016 Feb; 291(6):2799-811. PubMed ID: 26644477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
